Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02725476 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)
A Phase 2 study, sponsored by Xencor.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02725476 is a Phase 2 study that has completed, run by Xencor. The registered enrollment target is 20 participants.
The verdict
NCT02725476, a Phase 2 study, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this Phase 2 study is to investigate the effect of XmAb5871 on IgG4-Related Disease (RD) activity
Interventions
- BIOLOGICAL XmAb5871
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02725476
The ClinicalTrials.gov registry entry for NCT02725476 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XmAb5871 is the first listed.
NCT02725476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02725476 about?
NCT02725476 is a clinical study titled "Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)". The purpose of this Phase 2 study is to investigate the effect of XmAb5871 on IgG4-Related Disease (RD) activity
What is the current status of trial NCT02725476?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-03. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02725476?
The interventions under investigation include: XmAb5871 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02725476?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.